Story

Summit Therapeutics Shares Surge on Dual Positive Trial Results for Ivonescimab

ENTHMSVIIDZHZH-TWJAKOHI
Aug 26, 20262 min read
Summit Therapeutics Shares Surge on Dual Positive Trial Results for Ivonescimab
Text size
Background

Summit Therapeutics (NASDAQ: SMMT) saw its stock surge 8.5% in pre-open trading following a pair of significant positive clinical developments for its lead antibody, ivonescimab, which also prompted favorable analyst actions.

Dual Clinical Trial Success

The rally was driven by two key data releases. First, Summit's partner Akeso announced that the Phase III HARMONi-GI1 study for advanced biliary tract cancer met its primary endpoint. The trial showed that ivonescimab demonstrated a statistically significant improvement in overall survival compared to the current standard of care, durvalumab plus chemotherapy. This marks the first successful Phase III result for the drug outside of lung cancer.

Adding to the positive momentum, Summit published the primary analysis of its HARMONi Phase III trial in *The Lancet Oncology*. The study focused on patients with EGFR-mutated non-small cell lung cancer (NSCLC). Results showed that ivonescimab combined with chemotherapy reduced the risk of disease progression by nearly half when compared to a placebo, with a reported hazard ratio of 0.52.

Sample IUX Markets – In-articleAd

Analyst Upgrades and Market Impact

Wall Street analysts responded positively to the news. Guggenheim reiterated its "Buy" rating and $38 price target, stating that the biliary tract cancer results add consistency to ivonescimab's profile and build confidence for upcoming lung cancer programs. Separately, Bernstein SocGen upgraded the stock to "Market Perform" from "Underperform" and raised its price target to $11.90 from $9.80, reducing a significant source of institutional bearishness.

The stock's strong performance was company-specific, occurring while the broader market was subdued, with the S&P 500 trading flat. For investors, this convergence of a landmark clinical win in a new tumor type, a high-profile publication, and a shift in analyst sentiment creates a compelling catalyst. Attention will now turn to the next major binary event for the company: a U.S. Food and Drug Administration (FDA) decision expected in November.

Read next

More on Stocks
Back to latest news

LATEST